SARS-CoV-2 antibodies decline within 2 months
Antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) decline during the weeks after infection, in some cases falling below the threshold for seropositivity
The prevention, treatment, and management of illness and the preservation of mental and physical well-being through the services offered by the medical and allied health professions.
Antibodies to the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) decline during the weeks after infection, in some cases falling below the threshold for seropositivity
US is alerting clinical laboratory staff and health care providers that the FDA is monitoring the potential impact of viral mutations, including an emerging variant
The number of people coronavirus disease 2019 (COVID-19) is rising with more cases in the U.S. (5M according to the Centers for Disease Control and
The U.S. Food and Drug Administration approved Evenity (romosozumab-aqqg) to treat osteoporosis in postmenopausal women at high risk of breaking a bone (fracture). These are
Scientists want to know whether taking antibiotics early in life can disrupt your immune system function lifelong. Regardless of our age, antibiotics at least temporarily
U.S. Food and Drug Administration approved Anthim (obiltoxaximab) injection to treat inhalational anthrax in combination with appropriate antibacterial drugs. Anthim is also approved to prevent
Reducing consumption of added sugar has the power to reverse a cluster of chronic metabolic diseases, including high cholesterol and blood pressure, in children in
Many new mothers do not receive advice from physicians on aspects of infant care such as sleep position, breastfeeding, immunization and pacifier use, according to
Government of India has approved and notified National AYUSH Mission (NAM) for better access to AYUSH services; strengthening of AYUSH educational institutions, facilitate the enforcement
Sipuleucel-T in prostate cancer: Indication of added benefit – Sipuleucel-T (trade name Provenge) has been approved since September 2014 for men with metastatic prostate cancer who have few or no symptoms and do not yet require chemotherapy. In the dossier assessment conducted by the German Institute for Quality and Efficiency in Health Care (IQWiG) in January 2015, no added benefit could be derived for sipuleucel-T.